Head to head
Eli Lilly and Co vs Novo-Nordisk A/S
Side-by-side on the measures that matter, with a plain-English read. Full detail: LLY · NVO
LLY
Eli Lilly and Co
1,123.91-2.21%
Quant Rating B · 80/100 · 1-yr +53%
vs
NVO
Novo-Nordisk A/S
45.16-3.09%
Quant Rating C · 67/100 · 1-yr -13%
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the higher Quant Rating (80 vs 67); Novo-Nordisk A/S trades cheaper on trailing earnings; Eli Lilly and Co has done better over the past year (+53% vs -13%).
| LLY | NVO | |
|---|---|---|
| Last price | 1,123.91 | 45.16 |
| Change today | -2.21% | -3.09% |
| 1-year return | +53.1% | -12.8% |
| Market cap | $1.06T | $201.64B |
| P/E (TTM) | 37.73 | 11.08 |
| P/B | 31.23 | 5.86 |
| Dividend yield | 0.57% | 3.95% |
| EPS (TTM) | 22.95 | 3.58 |
| 52-week range | 707.59 – 1,292.65 | 34.20 – 61.21 |
| StockVane Quant Rating | B (80) | C (67) |
▲ marks the more favourable side on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Not a recommendation. Quant Rating method: Data & Methodology.